Zacks Research Weighs in on Pacira BioSciences, Inc.’s FY2026 Earnings (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRXFree Report) – Analysts at Zacks Research issued their FY2026 earnings per share estimates for Pacira BioSciences in a research report issued to clients and investors on Thursday, March 21st. Zacks Research analyst R. Department forecasts that the company will post earnings of $3.33 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.22 per share.

A number of other analysts have also recently weighed in on PCRX. Needham & Company LLC reiterated a “buy” rating and issued a $45.00 price target on shares of Pacira BioSciences in a research report on Friday, March 1st. TheStreet raised Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Raymond James initiated coverage on Pacira BioSciences in a research note on Wednesday, December 20th. They issued an “outperform” rating and a $42.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research note on Thursday, February 8th. Finally, Royal Bank of Canada reduced their price objective on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $49.50.

View Our Latest Analysis on PCRX

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX opened at $29.23 on Monday. The business’s fifty day moving average price is $30.34 and its two-hundred day moving average price is $30.39. Pacira BioSciences has a fifty-two week low of $25.93 and a fifty-two week high of $48.60. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of 36.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.24 and a quick ratio of 4.17.

Pacira BioSciences (NASDAQ:PCRXGet Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The firm had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at approximately $40,488,000. Pacer Advisors Inc. lifted its position in shares of Pacira BioSciences by 397,487.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company’s stock valued at $35,146,000 after buying an additional 1,041,417 shares during the last quarter. Prosight Management LP lifted its position in shares of Pacira BioSciences by 863.1% in the second quarter. Prosight Management LP now owns 877,586 shares of the company’s stock valued at $35,165,000 after buying an additional 786,463 shares during the last quarter. Millennium Management LLC lifted its position in shares of Pacira BioSciences by 146.1% in the fourth quarter. Millennium Management LLC now owns 1,151,754 shares of the company’s stock valued at $44,469,000 after buying an additional 683,680 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Pacira BioSciences by 852.7% in the 1st quarter. Wellington Management Group LLP now owns 676,365 shares of the company’s stock valued at $51,620,000 after purchasing an additional 605,370 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Gary W. Pace sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary W. Pace sold 90,000 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at $677,086.20. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

Pacira BioSciences Company Profile

(Get Free Report)

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.

Featured Stories

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.